TherapeuticsMD, Inc. — Director's Dealing 2021

Aug 13, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: TherapeuticsMD, Inc. (TXMD)
CIK: 0000025743
Period of Report: 2021-08-10

Reporting Person: DArecca James (Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-08-10	Common Stock	M	217167	—	Acquired	217167	Direct
2021-08-12	Common Stock	S	93337	$0.87	Disposed	123830	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-08-10	Restricted Stock Units	$0	M	217167	Disposed		Common Stock (217167)	Direct

Footnotes

F1: On August 10, 2021, the reporting person received 217,167 shares of common stock of the issuer in settlement of restricted stock units (RSUs), which vested on June 18, 2021.

F2: The reported securities represent shares of issuer common stock sold upon settlement to satisfy tax obligations.

F3: This transaction was executed in multiple trades at prices ranging from $0.87 to $0.88. The price reported in Column 4 reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

F4: Each RSU represents a contingent right to receive one share of issuer common stock upon settlement.

F5: The RSUs vest in three equal installments annually beginning June 1, 2021 (the one-year anniversary of the date of the reporting person's appointment as Chief Financial Officer), becoming fully vested on June 1, 2023.